By using this website you consent to our use of these cookies.
Key skills and capabilities
IMED Biotech Unit
Key skills and capabilities
Our ground-breaking research agenda brings together the brightest minds. We harness a unique mix of scientific skills and capabilities, bringing together people from diverse backgrounds and a rich variety of expertise.
We have a large and diverse oncology portfolio. We develop novel targeted monotherapies and combinations that address either the underlying mechanism of disease or how it evades effective immune response.
Cardiovascular, Renal and Metabolism
We have built knowledge in cardiovascular, renal and metabolic disease, and invested in key technologies to develop both our pipeline and our level of scientific expertise. This has been coupled with a patient-centric approach aimed at better understanding the interplay and potential causal relationship between these diseases, which often present in the same patient.
Our robust portfolio of early targets has the potential to transform the treatment of respiratory disease. Increasing our understanding of disease drivers forms the basis of our drug discovery programme and supports our vision to deliver disease modifying medicines that could prevent, reverse or even cure respiratory diseases.
We pursue opportunity-driven projects in neuroscience. Our business model thrives on being dynamic and partly externalised, with a laser-like focus driving science within our key areas of interest – neurodegenerative diseases, psychiatry and analgesia.
Our focus on discovery sciences ensures we can develop and deliver novel reagents and high-quality assays to support efficient and effective pre-clinical drug discovery and biomarker development in later clinical phases. In parallel, our screening capabilities provide project teams with insights across lead generation and lead optimisation projects, while our structure and biophysics group use protein structure and biophysics to understand the relationships between target protein and chemical space.
Drug safety and metabolism
We apply drug metabolism and pharmacokinetics (DMPK) expertise with discovery safety capabilities to ensure our teams accelerate the discovery and development of safe new molecules across our focus areas.
Early clinical development
We design and deliver development strategies and clinical studies that build the credentials of novel targets. The place where our science meets the patient, our early clinical development determines whether a promising compound is good enough to progress to Phase III.
Precision medicine and genomics
We investigate the genetic drivers of disease and develop innovative diagnostics. As a leader in precision medicine and genomics, we are driven by patient need, with a commitment to matching life changing medicines to patients most likely to benefit.
Supports our researchers and pipeline projects through strategic planning, drug project and portfolio management and ensuring our labs and facilities are served and maintained with science in mind.
Ensures we implement intelligent design of medicines and delivery systems. The team supports formulation and delivery for our portfolio across the main therapy areas, from early discovery to Phase IIb clinical trials.
Scientific Partnering and Alliances
Works across IMED to identify, prioritise, evaluate and access external innovation.
You are now leaving AstraZeneca.com
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.
You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.
I have read this warning and will not be using any of the contained product information for clinical purposes.